Cargando…

Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries

BACKGROUND: Although health technology assessment (HTA) systems base their decision making process either on economic evaluations or comparative clinical benefit assessment, a central aim of recent approaches to value measurement, including value based assessment and pricing, points towards the inco...

Descripción completa

Detalles Bibliográficos
Autores principales: Angelis, Aris, Lange, Ansgar, Kanavos, Panos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5773640/
https://www.ncbi.nlm.nih.gov/pubmed/28303438
http://dx.doi.org/10.1007/s10198-017-0871-0
_version_ 1783293604343578624
author Angelis, Aris
Lange, Ansgar
Kanavos, Panos
author_facet Angelis, Aris
Lange, Ansgar
Kanavos, Panos
author_sort Angelis, Aris
collection PubMed
description BACKGROUND: Although health technology assessment (HTA) systems base their decision making process either on economic evaluations or comparative clinical benefit assessment, a central aim of recent approaches to value measurement, including value based assessment and pricing, points towards the incorporation of supplementary evidence and criteria that capture additional dimensions of value. OBJECTIVE: To study the practices, processes and policies of value-assessment for new medicines across eight European countries and the role of HTA beyond economic evaluation and clinical benefit assessment. METHODS: A systematic (peer review and grey) literature review was conducted using an analytical framework examining: (1) ‘Responsibilities and structure of HTA agencies’; (2) ‘Evidence and evaluation criteria considered in HTAs’; (3) ‘Methods and techniques applied in HTAs’; and (4) ‘Outcomes and implementation of HTAs’. Study countries were France, Germany, England, Sweden, Italy, Netherlands, Poland and Spain. Evidence from the literature was validated and updated through two rounds of feedback involving primary data collection from national experts. RESULTS: All countries assess similar types of evidence; however, the specific criteria/endpoints used, their level of provision and requirement, and the way they are incorporated (e.g. explicitly vs. implicitly) varies across countries, with their relative importance remaining generally unknown. Incorporation of additional ‘social value judgements’ (beyond clinical benefit assessment) and economic evaluation could help explain heterogeneity in coverage recommendations and decision-making. CONCLUSION: More comprehensive and systematic assessment procedures characterised by increased transparency, in terms of selection of evaluation criteria, their importance and intensity of use, could lead to more rational evidence-based decision-making, possibly improving efficiency in resource allocation, while also raising public confidence and fairness. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10198-017-0871-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5773640
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-57736402018-01-30 Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries Angelis, Aris Lange, Ansgar Kanavos, Panos Eur J Health Econ Original Paper BACKGROUND: Although health technology assessment (HTA) systems base their decision making process either on economic evaluations or comparative clinical benefit assessment, a central aim of recent approaches to value measurement, including value based assessment and pricing, points towards the incorporation of supplementary evidence and criteria that capture additional dimensions of value. OBJECTIVE: To study the practices, processes and policies of value-assessment for new medicines across eight European countries and the role of HTA beyond economic evaluation and clinical benefit assessment. METHODS: A systematic (peer review and grey) literature review was conducted using an analytical framework examining: (1) ‘Responsibilities and structure of HTA agencies’; (2) ‘Evidence and evaluation criteria considered in HTAs’; (3) ‘Methods and techniques applied in HTAs’; and (4) ‘Outcomes and implementation of HTAs’. Study countries were France, Germany, England, Sweden, Italy, Netherlands, Poland and Spain. Evidence from the literature was validated and updated through two rounds of feedback involving primary data collection from national experts. RESULTS: All countries assess similar types of evidence; however, the specific criteria/endpoints used, their level of provision and requirement, and the way they are incorporated (e.g. explicitly vs. implicitly) varies across countries, with their relative importance remaining generally unknown. Incorporation of additional ‘social value judgements’ (beyond clinical benefit assessment) and economic evaluation could help explain heterogeneity in coverage recommendations and decision-making. CONCLUSION: More comprehensive and systematic assessment procedures characterised by increased transparency, in terms of selection of evaluation criteria, their importance and intensity of use, could lead to more rational evidence-based decision-making, possibly improving efficiency in resource allocation, while also raising public confidence and fairness. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10198-017-0871-0) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2017-03-16 2018 /pmc/articles/PMC5773640/ /pubmed/28303438 http://dx.doi.org/10.1007/s10198-017-0871-0 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Paper
Angelis, Aris
Lange, Ansgar
Kanavos, Panos
Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries
title Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries
title_full Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries
title_fullStr Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries
title_full_unstemmed Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries
title_short Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries
title_sort using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight european countries
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5773640/
https://www.ncbi.nlm.nih.gov/pubmed/28303438
http://dx.doi.org/10.1007/s10198-017-0871-0
work_keys_str_mv AT angelisaris usinghealthtechnologyassessmenttoassessthevalueofnewmedicinesresultsofasystematicreviewandexpertconsultationacrosseighteuropeancountries
AT langeansgar usinghealthtechnologyassessmenttoassessthevalueofnewmedicinesresultsofasystematicreviewandexpertconsultationacrosseighteuropeancountries
AT kanavospanos usinghealthtechnologyassessmenttoassessthevalueofnewmedicinesresultsofasystematicreviewandexpertconsultationacrosseighteuropeancountries